Abstracts tagged "proteomics"

Abstract Number: 1571 • ACR Convergence 2024
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Vishal Kakkar¹, Sunhwa Kim², Yingtao Bi³, Christopher Wasson¹, Stefano Di Donato⁴, Rebecca Ross⁵, Marco Di Battista⁶, Enrico De Lorenzis⁷, Thierry Sornasse² and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²AbbVie, South San Francisco, CA, ³Abbvie, Worcester, MA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, ⁷Catholic University of the Sacred Heart, Roma, Rome, Italy
Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
Abstract Number: 2487 • ACR Convergence 2024
Comparing Circulating Protein Profiles in Patients with Active Myeloperoxidase (MPO) vs Proteinase-3 (PR3) Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
Colebrook Johnson¹, David O'Dea¹, Natalie Atallah¹, Gary Reynolds¹, Bohang Jiang¹, Shruthi Srivatsan¹, Zachary Williams¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA type (e.g., PR3-, MPO-ANCA) may be a better way to subgroup patients with ANCA-associated vasculitis (AAV) than phenotype (e.g., granulomatosis with polyangiitis [GPA]).…
Abstract Number: 0416 • ACR Convergence 2024
Proteomic Signatures of Synovial Fluid in Different Subtypes of Juvenile Idiopathic Arthritis
narendra bagri¹, saumya srivastava², yogendra singh², Thirumurthy Velpandian², Ashish Upadhyay², venkatesan sampath kumar², Subhradip Karmakar² and sushil K Kabra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²AIIMS New Delhi, new delhi, India
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is heterogenous group of inflammatory disorder with clinically distinct subtypes; polyarticular, oligoarticular systemic onset JIA (sJIA), and enthesitis-related arthritis (ERA).…
Abstract Number: 1654 • ACR Convergence 2024
CRTAC1 in Osteoarthritis: Implications for Disease Severity and miRNA Regulation
Aneta Prokopcová¹, Jiri Baloun², Adéla Navrátilová³, Klára Mocová², Lucia Ondrejčáková⁴, Jana Juhaszova², Tereza Kropáčková¹, Hana Storkanova⁵, Michal Tomcik⁵, Jindriska Gatterova², Olga Sleglova², Olga Ruzickova², Eva Kriegova⁶, Jiri Gallo⁷, Rastislav Ballay⁸, Petr Fulin⁹, Jiří Vencovský¹ and Ladislav Šenolt¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³1st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia, Olomouc, Czech Republic, ⁷Department of Orthopaedics, University Hospital Olomouc, Olomouc, Czech Republic, ⁸1st Faculty of Medicine, Charles University, Prague, Czechia, Prague, Czech Republic, ⁹1st Department of Orthopaedics, First Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czechia, Prague, Czech Republic
Background/Purpose: Cartilage acidic protein1 (CRTAC1) is a potential biomarker linked to osteoarthritis (OA) and cartilage degeneration. This study aimed to compare CRTAC1 levels in the…
Abstract Number: 2535 • ACR Convergence 2024
The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation
Chary Lopez-Pedrera¹, Beatriz Vellón-García², Mª Angeles Aguirre-Zamorano³, Sagrario Corrales⁴, Ismael Sánchez Pareja⁴, Laura Muñoz-Barrera⁴, Tomás Cerdó⁴, Pedro Segui⁵, Christian Merlo⁵, María del carmen ábalos-Aguilera⁵, Nuria Barbarroja⁴, Alejandro Escudero-Contreras⁶, Rafaela Ortega-Castro⁷, José Manuel Villalba⁸ and Carlos Perez-Sanchez⁴, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ²Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3) / Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ⁶Reina Sofia University Hospital, Córdoba, Spain, ⁷Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁸Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3), Cordoba, Spain
Background/Purpose: This study aims to:1) Characterize the circulating lipidomic and proteomic profiles of APS patient and analyse its association with clinical features.2) Investigate the short-term…
Abstract Number: 0444 • ACR Convergence 2024
Deep Serologic Profiling Identifies Novel Autoantibodies Associated with Fetal Atrioventricular Block
Philip Carlucci¹, Robert Clancy², Mala Masson³, Colin Phoon⁴, Ashley Roman⁴, Peter Izmirly⁵, Amit Saxena⁶, H Michael Belmont⁴, Christina Penfield⁴, Young Mi Lee⁴, Julie Nusbaum⁷, Andrew Rubenstein⁴, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Abuhamad⁹, Karla Bermudez-Wagner⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Whitnee Hogan¹², Nelangi Pinto¹³, Anita Moon-Grady¹⁴, Lisa Howley¹⁵, Mary Donofrio¹⁶, Anita Krishnan¹⁶, Jaclyn Phillips¹⁷, Stephanie Levasseur¹⁸, Miwa Geiger¹⁹, Erin Paul²⁰, Sonal Owens²¹, Kristopher Cumbermack²², Jyothi Matta²³, Gary Joffe²⁴, Christopher Lindblade²⁵, Carl Weiner²⁶, Caitlin Haxel²⁷, Katherine Kohari²⁸, Joshua Copel²⁸, James Strainic²⁹, Tam Doan³⁰, Shreya Sheth³⁰, Stacy Killen³¹, Theresa Tacy³², Michelle Kaplinski³², Nicola Fraser⁴, Kelly Ruggles³³, Bettina Cuneo³⁴ and Jill Buyon³⁵, ¹New York University School of Medicine, New York, NY, ²Columbia University Medical Center, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Langone Hospital - Long Island, Internal Medicine - Rheumatology, Mineola, NY, ⁸Children's Heart Center, Las Vegas, NV, ⁹Eastern Virginia Medical School, Norfolk, VA, ¹⁰Atrium Health Levine Children's Hospital, Charlotte, NC, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, UT, ¹³Seattle Children's Hospital, Seattle, WA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁶Children's National Hospital, Washington, DC, ¹⁷George Washington University, Washington, DC, ¹⁸Columbia University, New York, NY, ¹⁹Mount Sinai School of Medicine, New York, NY, ²⁰Atlantic Health System, Morristown, NJ, ²¹University of Michigan, Ann Arbor, MI, ²²University of Kentucky, Lexington, KY, ²³University of Louisville, Louisville, KY, ²⁴Perinatal Associates of New Mexico, Albuquerque, NM, ²⁵Phoenix Children's Hospital, Phoenix, AZ, ²⁶Dignity Health, Phoenix, AZ, ²⁷University of Vermont Children's Hospital, Burlington, VT, ²⁸Yale University, New Haven, CT, ²⁹UH Rainbow Babies, Cleveland, OH, ³⁰Baylor College of Medicine, Houston, TX, ³¹Vanderbilt University, Nashville, TN, ³²Stanford University, Stanford, CA, ³³NYU Grossman School of Medicine, Brooklyn, NY, ³⁴University of Arizona College of Medicine, Tucson, AZ, ³⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Maternal anti-SSA/Ro52/60kD autoantibodies are necessary for the development of fetal atrioventricular block (AVB) but titers alone are not sufficient to predict the likelihood of…
Abstract Number: 1686 • ACR Convergence 2024
Urine Proteomics in Class II Lupus Nephritis Reveals Immune Activation and Pro-Fibrotic Signatures
Jasmine Shwetar¹, Jill Buyon², Michelle Petri³, Kelly Ruggles⁴ and Andrea Fava⁵, ¹New York School of Medicine, Ann Arbor, MI, ²NYU Grossman School of Medicine, New York, NY, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU Grossman School of Medicine, Brooklyn, NY, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is a pathologically diverse autoimmune disease that can lead to end-stage kidney disease and mortality. Although Class II LN is considered…
Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Natalie McCormick¹, Amit Joshi², Robert Terkeltaub³, Tony Merriman⁴, Matthew Nayor⁵, Chio Yokose⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Waltham, MA, ⁷Massachusetts General Hospital, Lexington, MA
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…
Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Andrea Fava¹, Michelle Petri², David Jayne³, Patrick G Gavin⁴, Eszter Csomor⁵, Philip Z Brohawn⁴, Daniel Muthas⁶, Adam Platt⁵, Catharina Lindholm⁷ and Nicola Ferrari⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of Cambridge, Cambridge, United Kingdom, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
Abstract Number: 1687 • ACR Convergence 2024
IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Ioannis Parodis¹, Dionysis Nikolopoulos², Julius Lindblom³, Denis Lagutkin³, Lorenzo Beretta⁴, Maria Orietta Borghi⁵, Janique Peyper⁶, Guillermo Barturen⁷, Per-Johan Jakobsson³, Marta Alarcon-Riquelme⁸, Natalia Sherina³ and Helena Idborg⁹, and PRECISESADS Clinical Consortium, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁵Università degli Studi di Milano Statale, Milano, Italy, ⁶Sengenics Corporation Pte Ltd, Singapore, Singapore, ⁷Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁸Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁹Karolinska Institutet, Solna, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
Abstract Number: 2636 • ACR Convergence 2024
Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Stephen Pennington¹, Ruoyi Zhou², Jonathan Brady², Bruna Wundervald², Andrew Parnell³, Ciarán Duffy², Robert Perryman², James Waddington⁴, Neil McHugh⁵, Deepak Jadon⁶, David Simon⁷, Filippo Fagni⁸, Georg Schett⁹, Fraser Morton¹⁰, Aurelie Najm¹⁰, Stefan Siebert¹¹, Laura Coates¹² and Oliver FitzGerald¹³, ¹UCD, Dublin, Dublin, Ireland, ²Atturos, DUBLIN, Dublin, Ireland, ³NUIM, Maynooth, Ireland, ⁴Agilent, Manchester, United Kingdom, ⁵University of Bath, Bath, United Kingdom, ⁶Cambridge University, Cambridge, United Kingdom, ⁷Charité - Universittsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹³UCD, Dublin 6, Dublin, Ireland
Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…
Abstract Number: 0861 • ACR Convergence 2023
The Analgesic Effect of RC-0165, a TRPV1 Antagonist, for Osteoarthritis Pain
Donghui kim, Juil park, Minjung kim and Yongho kim, RudaCure, Seoul, South Korea
Background/Purpose: Osteoarthritis (OA), the most common form of arthritis, arises from the deterioration of cartilage within joint bones, resulting in pain and functional disability with…
Abstract Number: 2042 • ACR Convergence 2023
Intraocular Cytokine Profiling of Autoimmune Uveitis
Maryrose Hahn¹, Madison Mangin², Marc Todd¹, Pui Lee¹, Mindy Lo¹, Bharti Gangwani³, Ankoor Shah³, Amanda Colombo⁴, Jessica Scott⁴, Stephen Anesi⁴, C. Stephen Foster⁴, Peter Chang⁴, Peter Nigrovic² and Margaret Chang², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Department of Ophthalmology, Boston Children's Hospital, Boston, MA, ⁴Massachusetts Eye Research and Surgery Institution, Waltham, MA
Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…
Abstract Number: 0915 • ACR Convergence 2023
IL-16+ Is Abundantly Expressed by Kidney-infiltrating Myeloid and Lymphoid Cells in Lupus Nephritis: A Spatially Resolved Multiplexed Approach
Alessandra Ida Celia¹, Xiaoping Yang², Hana Minsky², Silvia Malvica², Michelle Petri³, the Accelerating Medicines Partnership in RA/SLE⁴, Avi Rosenberg⁵ and Andrea Fava², ¹John Hopkins University of Medicine, Rome, Italy, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴Multiple, Multiple, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We previously discovered that IL-16 is the urinary protein most strongly correlated with histological activity in lupus nephritis (LN), followed by neutrophil degranulation products…
Abstract Number: 2355 • ACR Convergence 2023
Proteome-based Stratification of Therapeutic Target Population for MT-6194 in Systemic Sclerosis with Pulmonary Arterial Hypertension
Yuuichi Ono¹, Akira Mogami¹, Ryuta Saito², Noriyasu Seki¹, Sho Ishigaki³, Hiroshi Takei³, Keiko Yoshimoto³, Kenji Chiba¹, Tsutomu Takeuchi⁴ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ²Mitsubishi Tanabe Pharma Corporaion, Yokohama, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: SSc-related pulmonary arterial hypertension (SSc-PAH) is the one of the leading causes of death in SSc. Early diagnosis and effective therapy for SSc-PAH may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].